HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: To date, the U.S. Food and Drug Administration approves two HDAC inhibitors, vorinostat (SAHA, suberoylanilide hydroxamic acid, Zolinza®) and romidepsin (FK228, depsipeptide, Istodax®), for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) [12].